Comparison of no adjuvant treatment and radiotherapy in early-stage cervical carcinoma with intermediate risk factors

被引:17
作者
Akilli, Huseyin [1 ]
Tohma, Yusuf A. [2 ]
Bulut, Ayca N. [3 ]
Karakas, Latife Atasoy [2 ]
Haberal, Asuman N. [4 ]
Kuscu, Ulku E. [1 ]
Ayhan, Ali [1 ]
机构
[1] Baskent Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Sch Med, Ankara, Turkey
[2] Baskent Univ, Dept Obstet & Gynecol, Sch Med, Ankara, Turkey
[3] City Hosp, Dept Obstet & Gynecol, Kayseri, Turkey
[4] Baskent Univ, Dept Pathol, Sch Med, Ankara, Turkey
关键词
Adjuvant treatment; Disease-free survival; Early-stage cervical cancer; Intermediate risk factors; Local recurrence; Radiotherapy; RADICAL HYSTERECTOMY; RADIATION-THERAPY; CANCER-PATIENTS; IB; CHEMOTHERAPY; SURGERY;
D O I
10.1002/ijgo.13147
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the results of receiving no adjuvant treatment (NAT) or radiotherapy after radical hysterectomy in patients with International Federation of Gynecology and Obstetrics 2018 Stage IB1-IB3 cervical cancer with intermediate risk factors. Methods A retrospective cohort study was conducted at Baskent University School of Medicine's Department of Gynecology and Obstetrics in Ankara, Turkey between January 1, 2008, and December 31, 2016. In total, 134 women with at least two intermediate risk factors (positive LVSI, deep stromal invasion, and tumor size >= 4 cm) were included in the study. Patients were divided into two groups: NAT and radiotherapy. Results There were 66 patients in the NAT group and 68 in the radiotherapy group. The median follow-up time was 61.05 months. The 5-year overall survival (OS) rates were similar in both groups (84.1% vs 82.9%, respectively; P=0.57), while the 5-year disease-free survival (DFS) rates were 80.2% and 78.2% in the NAT and radiotherapy groups, respectively (P=0.25). Most importantly, both groups had similar local recurrence rates: 8 (12.1%) in the NAT group and 9 (13.2%) in the radiotherapy group (P=0.82). Multivariant analyses showed that the only independent risk factor for recurrence was tumor size >= 4 cm with a hazard ratio of 2.4 (95% confidence interval 1.12-5.24; P=0.02). Conclusion Adjuvant treatment improved neither DFS nor local recurrence rates.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 19 条
[11]   Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study [J].
Pieterse, Q. D. ;
Trimbos, J. B. M. Z. ;
Dijkman, A. ;
Creutzberg, C. L. ;
Gaarenstroom, K. N. ;
Peters, A. A. W. ;
Kenter, G. G. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (03) :1112-1118
[12]   2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy [J].
Querleu, Denis ;
Cibula, David ;
Abu-Rustum, Nadeem R. .
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (11) :3406-3412
[13]   Radiotherapy and chemoradiation after surgery for early cervical cancer [J].
Rogers, Linda ;
Siu, Shing Shun N. ;
Luesley, David ;
Bryant, Andrew ;
Dickinson, Heather O. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (05)
[14]   Incidence of radiation toxicity in cervical cancer and endometrial cancer patients treated with radiotherapy alone versus adjuvant radiotherapy [J].
Roszak, Andrzej ;
Warenczak-Florczak, Zaneta ;
Bratos, Krystyna ;
Milecki, Piotr .
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2012, 17 (06) :332-338
[15]   Stage IB and IIA cervical cancer with negative lymph nodes: The role of adjuvant radiotherapy after radical hysterectomy [J].
Schorge, JO ;
Molpus, KL ;
Koelliker, D ;
Nikrui, N ;
Goodman, A ;
Fuller, AF .
GYNECOLOGIC ONCOLOGY, 1997, 66 (01) :31-35
[16]   A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage is carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A gynecologic oncology group study [J].
Sedlis, A ;
Bundy, BN ;
Rotman, MZ ;
Lentz, SS ;
Muderspach, LI ;
Zaino, RJ .
GYNECOLOGIC ONCOLOGY, 1999, 73 (02) :177-183
[17]   Assessment of local treatment modalities for FIGO stage IB-IIB cervical cancer: A propensity-score matched analysis based on SEER database [J].
Song, Xing ;
Han, Yang ;
Shao, Yingjie ;
Gu, Wendong ;
Pei, Honglei ;
Jiang, Jingting .
SCIENTIFIC REPORTS, 2017, 7
[18]   Adjuvant chemotherapy after surgery can improve clinical outcomes for patients with IB2-IIB cervical cancer with neoadjuvant chemotherapy followed by radical surgery [J].
Sun, Haiying ;
Huang, Kecheng ;
Tang, Fangxu ;
Li, Xiong ;
Wang, Xiaoli ;
Long, Sixiang ;
Zhou, Shasha ;
Suolangquzhen ;
Zhang, Jianwei ;
Ning, Ruoqi ;
Li, Shuang ;
Wang, Shixuan ;
Ma, Ding .
SCIENTIFIC REPORTS, 2018, 8
[19]  
Tuipae Suphet, 2012, J Med Assoc Thai, V95 Suppl 3, pS117